BLISS GVS PHARMA LTD.



August 22, 2024

To,

The Manager, Listing Department

National Stock Exchange of India Limited

Plot no. C/1 G Block,

Bandra-Kurla Complex, Bandra (East),

Mumbai- 400 051 Symbol: **BLISSGVS**

To,

The General Manager, Listing Department

BSE Limited

Phiroze Jeejeebhoy Towers,

Dalal Street, Mumbai- 400 001

Scrip Code: **506197**

Dear Sir/Madam,

Subject: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 ("SEBI Listing Regulations")

Pursuant to Regulation 30 of the SEBI Listing Regulations, this is to inform you that BSE Limited ("BSE") and the National Stock Exchange of India Limited ("NSE"), through their letters dated August 21, 2024 (received by us around 06:50 PM and 10:20 PM, respectively), have each imposed a fine of Rs. 18,000/- (Rupees Eighteen Thousand only) (excluding GST) on the Company for noncompliance with Regulation 17(1A) of the SEBI Listing Regulations. The said fine comprised 0.000267% of the market capitalization of the Company.

We would like to bring to your attention that the Company has already provided responses to the Stock Exchanges, including the submission of the orders of the Securities Appellate Tribunal ('SAT') to NSE outlining the entire matter and the Company's stance. Despite this, both NSE and BSE have issued notices regarding non-compliance with SEBI (LODR) Regulation, 2015 and imposed penalties as per circular no. SEBI/HO/CFD/PoD2/CIR/P/2023/120 dated July 11, 2023 (Chapter-VII(A) -Penal Action for Non-Compliance).

Please be informed that the Company is actively addressing this issue by applying for a waiver and even appealing to the appropriate appellate authority, if required.

The details as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular SEBI/HO/CFD/CFD-PoD-1/P/CIR/2023/123 dated 13th July, 2023 are provided herewith 'Annexure-I'.

Kindly take the above intimation on record.

Yours Faithfully,

For Bliss GVS Pharma Limited

Deepak Sawant Chief Financial Officer

Encl: As above

Regd. Office: 102, Hyde Park, Saki Vihar Road, Andheri (East), Mumbai - 400 072, INDIA.

TEL.: (+91) (22) 42160000/ 28505387 • FAX.: (+91) (22) 28563930,

Email: info@blissgvs.com • Website: www.blissgvs.com • CIN - L24230MH1984PLC034771

Factory: Plot No. 10, 11 & 12, Survey No. 38/1, Dewan Udyog Nagar, Aliyali Village, Tal. & Dist. Palghar - 401 404.

Tel. (+91) (02525) 252713 • Fax: (+91) (02525) 255257. • Email: factory@blissgvs.com

BLISS GVS PHARMA LTD.



Annexure - I

Sr. No.	Particulars	Details
i.	Name of the authority	BSE and NSE
ii.	Nature and details of the action(s) taken, initiated or order(s) passed	A fine of Rs. 18,000/- (excluding GST) by each BSE and NSE.
iii.	Date of receipt of direction or order, including any ad-interim or interim orders, or any other communication from the authority	August 21, 2024 (BSE at about 06:50 PM and NSE at about 10:20 PM)
iv.	Details of the violation(s)/ contravention(s) committed or alleged to be committed	Regulation 17(1A) Non-compliance with the requirements pertaining to appointment or continuation of non-executive director who has attained the age of seventy-five years
v	Impact on financial, operation or other activities of the listed entity, quantifiable in monetary terms to the extent possible.	Nil, except to the extent of the fine imposed by BSE and NSE.

Regd. Office: 102, Hyde Park, Saki Vihar Road, Andheri (East), Mumbai - 400 072, INDIA.

TEL.: (+91) (22) 42160000/ 28505387 • FAX.: (+91) (22) 28563930,

Email: info@blissgvs.com • Website: www.blissgvs.com • CIN - L24230MH1984PLC034771

Factory: Plot No. 10, 11 & 12, Survey No. 38/1, Dewan Udyog Nagar, Aliyali Village, Tal. & Dist. Palghar - 401 404.

Tel. (+91) (02525) 252713 • Fax: (+91) (02525) 255257. • Email: factory@blissgvs.com